Effects of GLP-1 Receptor Agonists on Psoriasis: An “Agent-Specific” Systematic Review of the Literature
Journal of Clinical Medicine · 01.07.2026 · 15 (13) · 5126
DOI: 10.3390/jcm15135126 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 01.07.2026. Verfasst von Andrea Marani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dermatologic Unit, Department of Surgery, AUSL Romagna, 47923 Rimini, Italy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Psoriasis is a chronic inflammatory disease frequently associated with obesity and type 2 diabetes mellitus (T2DM). Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for T2DM and obesity, have demonstrated anti-inflammatory and immunomodulatory properties that may be relevant in psoriasis. However, individual GLP-1RAs differ substantially in their pharmacological characteristics and clinical effects. Our objective was to systematically review the available evidence on the effects of individual GLP-1RAs in patients with psoriasis.
Methods
A systematic review was conducted according to PRISMA 2020 guidelines. PubMed and Scopus were searched up to April 2026 for studies evaluating GLP-1RAs in psoriasis. Case reports, case series, observational studies, and randomized controlled trials were included. Preclinical, clinical and safety outcomes were extracted and narratively synthesized.
Results
Twenty-six studies met the inclusion criteria. Most involved patients with concomitant obesity and/or T2DM. Overall, semaglutide, liraglutide, exenatide, and tirzepatide were associated with improvements in psoriasis severity, often accompanied by reductions in body weight, glycated haemoglobin, inflammatory markers, and cardiometabolic risk factors. Semaglutide and liraglutide showed the most consistent evidence of benefit. Experimental and clinical data also suggested direct immunomodulatory effects on pathways involved in psoriasis pathogenesis. However, paradoxical psoriasiform eruptions and psoriasis exacerbations were reported with some agents. The evidence base was limited by the predominance of case reports and small observational studies, substantial heterogeneity, and the limited availability of randomized controlled trials.
Conclusions
Current evidence suggests that GLP-1RAs may improve both psoriatic disease activity and cardiometabolic outcomes, particularly in patients with obesity or T2DM. Nevertheless, potential differences among individual agents warrant further investigation in larger controlled studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dermatologic Unit, Department of Surgery, AUSL Romagna, 47923 Rimini, Italy.
- Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, 44124 Ferrara, Italy.
- Clinic of Dermatology, Department of Medicine and Aging Sciences, University G. d'Annunzio, 66100 Chieti, Italy.
- Dermatology Unit, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.
ORCID-Profile: Andrea Marani, Edvige Morea, Davide Bertolla, Giulio Gualdi, Alessandro Borghi, Andrea Conti, Paolo Amerio
Zitieren
APA
Marani, A., Neri, E., Morea, E., Bertolla, D., Gualdi, G., Borghi, A., Conti, A., & Amerio, P. (2026). Effects of GLP-1 Receptor Agonists on Psoriasis: An “Agent-Specific” Systematic Review of the Literature. Journal of Clinical Medicine, 15(13), 5126. https://doi.org/10.3390/jcm15135126
Vancouver
Marani A, Neri E, Morea E, Bertolla D, Gualdi G, Borghi A, et al. Effects of GLP-1 Receptor Agonists on Psoriasis: An “Agent-Specific” Systematic Review of the Literature. Journal of Clinical Medicine. 2026;15(13):5126. doi:10.3390/jcm15135126
BibTeX
@article{Marani2026,
author = {Marani, Andrea and Neri, Eleonora and Morea, Edvige and Bertolla, Davide and Gualdi, Giulio and Borghi, Alessandro and Conti, Andrea and Amerio, Paolo},
title = {Effects of GLP-1 Receptor Agonists on Psoriasis: An “Agent-Specific” Systematic Review of the Literature},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {13},
pages = {5126},
doi = {10.3390/jcm15135126}
}
EUVIMED